论文部分内容阅读
目的:评估进展性脑梗塞采取奥扎格雷钠联合巴曲酶治疗的效果。方法:将72例进展性脑梗死患者作为研究的对象,按随机数字表法分为两组;对照组36例单用奥扎格雷钠治疗,观察组36例采取奥扎格雷钠联合巴曲酶治疗;对比两组患者临床疗效以及治疗前后神经功能缺损(NIHSS)评分情况。结果:观察组治疗总有效率(94.44%)明显高于对照组(77.78%,P<0.05)。治疗后,两组患者NIHSS评分均有所下降,但观察组下降幅度显著高于对照组(P<0.05)。结论:进展性脑梗死患者采取奥扎格雷钠联合巴曲酶治疗效果显著,值得采纳应用。
OBJECTIVE: To assess the effect of sodium ozagrel combined with batroxobin on patients with progressive cerebral infarction. Methods: Seventy-two patients with progressive cerebral infarction were divided into two groups according to the random number table. In the control group, 36 patients were treated with ozagrel sodium alone. In the observation group, 36 patients received sodium ozagrel and batroxobin The clinical efficacy and NIHSS scores of two groups were compared. Results: The total effective rate (94.44%) in the observation group was significantly higher than that in the control group (77.78%, P <0.05). After treatment, NIHSS scores decreased in both groups, but the decrease in observation group was significantly higher than that in control group (P <0.05). Conclusion: Ozagrel sodium combined with batroxobin is effective in patients with progressive cerebral infarction, which is worthy of adoption.